Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition

AI Summary

Roth/MKM downgraded Apellis Pharmaceuticals (APLS) following Biogen's acquisition, citing concerns over competitive pressures. This action reflects broader market sentiment regarding APLS's growth prospects in the wake of the acquisition. Specific data points and projections were not included in the downgrade, leading to uncertainty among investors. The market will be closely monitoring APLS's response and performance in the coming quarters, impacting stock movements and investor confidence.